TY - JOUR
T1 - Smokeless Tobacco and Cigar and/or Pipe Are Risk Factors for Barrett Esophagus in Male Patients With Gastroesophageal Reflux Disease
AU - Westra, Wytske M.
AU - Lutzke, Lori S.
AU - Mostafavi, Nahid S.
AU - Roes, Alev L.
AU - Calpe, Silvia
AU - Wang, Kenneth K.
AU - Krishnadath, Kausilia K.
N1 - Funding Information:
Grant Support: The work was supported by grant U01 CA182940 (K.K.W.) from NCI and by the Dutch Cancer Foundation/KWF kankerbestrijding (K.K.K.)
Publisher Copyright:
© 2018 Mayo Foundation for Medical Education and Research
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2018/9
Y1 - 2018/9
N2 - Objective: To investigate the effect of smokeless tobacco (ST), cigar and/or pipe smoking (CP) on the development of Barrett esophagus (BE) in white male patients with gastroesophageal reflux disease (GERD). Patients and Methods: A total of 1015 records of white male adults with BE (cases; n=508) or GERD (controls, n=507) were reviewed for lifestyle factors. Logistic regression analyses were performed after adjusting for lifestyle factors to assess the effects of ST and CP on the risk of developing BE. Differences between patients with BE and those with GERD were compared using chi-square and t tests. Results: Patients with BE were significantly older than patients with GERD (mean age, 66±12 years for patients with BE and 55±15 years for patients with GERD; P<.001). The odds of developing BE in patients who used CS were 1.7 times higher than that in patients who never smoked cigarettes (odds ratio [OR], 1.7; 95% CI, 1.3-2.2). It was observed that when CS use was combined with either ST or CP use, the odds of having BE significantly increased (OR, 2.5; 95% CI, 1.2-5.2; P=.01 and OR, 1.9; 95% CI, 1.03-3.58; P=.04) in comparison to CS alone. There were no significant differences in body mass index and alcohol consumption between BE and GERD groups. Conclusion: This study suggests that there is indeed an association between CS and BE. We believe that this is the first time that ST and CP were associated with an even higher odds of developing BE. Further studies are needed to investigate whether the use of ST and CP is also associated with an increased risk of developing BE-associated adenocarcinoma.
AB - Objective: To investigate the effect of smokeless tobacco (ST), cigar and/or pipe smoking (CP) on the development of Barrett esophagus (BE) in white male patients with gastroesophageal reflux disease (GERD). Patients and Methods: A total of 1015 records of white male adults with BE (cases; n=508) or GERD (controls, n=507) were reviewed for lifestyle factors. Logistic regression analyses were performed after adjusting for lifestyle factors to assess the effects of ST and CP on the risk of developing BE. Differences between patients with BE and those with GERD were compared using chi-square and t tests. Results: Patients with BE were significantly older than patients with GERD (mean age, 66±12 years for patients with BE and 55±15 years for patients with GERD; P<.001). The odds of developing BE in patients who used CS were 1.7 times higher than that in patients who never smoked cigarettes (odds ratio [OR], 1.7; 95% CI, 1.3-2.2). It was observed that when CS use was combined with either ST or CP use, the odds of having BE significantly increased (OR, 2.5; 95% CI, 1.2-5.2; P=.01 and OR, 1.9; 95% CI, 1.03-3.58; P=.04) in comparison to CS alone. There were no significant differences in body mass index and alcohol consumption between BE and GERD groups. Conclusion: This study suggests that there is indeed an association between CS and BE. We believe that this is the first time that ST and CP were associated with an even higher odds of developing BE. Further studies are needed to investigate whether the use of ST and CP is also associated with an increased risk of developing BE-associated adenocarcinoma.
UR - http://www.scopus.com/inward/record.url?scp=85052539418&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052539418&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2018.04.022
DO - 10.1016/j.mayocp.2018.04.022
M3 - Article
C2 - 30193675
AN - SCOPUS:85052539418
SN - 0025-6196
VL - 93
SP - 1282
EP - 1289
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 9
ER -